Impact of COVID-19 on lung cancer care in New South Wales, Australia: real-world data from the EnRICH Program

被引:0
|
作者
Brown, Bea [1 ]
Young, Jane [2 ]
Galpin, Kirsty [3 ]
Boyer, Michael [4 ]
Chin, Venessa [5 ,6 ]
Brown, Chris [1 ]
Simes, Robert J. [1 ]
机构
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[2] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia
[3] Univ Sydney, Sch Psychol, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW, Australia
[4] Chris OBrien Lifehouse, Sydney, NSW, Australia
[5] St Vincents Hosp, Sydney, NSW, Australia
[6] Garvan Inst Med Res, Sydney, NSW, Australia
来源
PUBLIC HEALTH RESEARCH & PRACTICE | 2024年 / 34卷 / 03期
关键词
UK;
D O I
10.17061/phrp3432423
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: The coronavirus disease 2019 (COVID-19) pandemic disrupted healthcare systems worldwide, causing substantial changes to routine healthcare delivery. National and international modelling studies have predicted adverse impacts of this disruption. This study aimed to assess the real-world impact of the COVID-19 pandemic on quality of care and outcomes for patients with lung cancer in New South Wales (NSW). Study type: Pre-post observational cohort study using data prospectively collected for the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) Program. Methods: The study population comprised 2000 patients with lung cancer from six specialist cancer centres in metropolitan and regional NSW. We split this population into two cohorts: the pre-COVID-19 cohort (1143 patients diagnosed from 8 September 2016 to 10 March 2020) and the post-COVID-19 cohort (857 patients diagnosed from 11 March 2020 to 28 October 2021). The main outcome measures were lung cancer clinical quality indicators, 1-year and 2-year overall survival, and patient-reported health-related quality of life and psychological distress. Results: Patient and disease characteristics (e.g. age, gender, cancer stage) were similar for the pre-and post-COVID-19 cohorts, except for histology (non- small cell lung cancer (NSCLC) 88% in the pre-COVID-19 cohort and 84% in the post-COVID-19 cohort; p = 0.008) and region of residence (62% and 55%, respectively, lived in metropolitan areas; p = 0.002). Compared to the pre-COVID-19 cohort, fewer patients in the post-COVID-19 cohort received a diagnosis within 28 days of the first investigation of symptoms (clinical diagnosis: 77% compared with 72%; p = 0.017, pathological diagnosis: 60% compared with 53%; p = 0.005). However, the median time from the first investigation of symptoms to treatment initiation did not differ. One- and 2-year overall survival, quality of life and psychological distress did not differ between cohorts. Conclusions: This analysis found that the COVID-19 pandemic did not significantly adversely affect quality of care and outcomes for patients with lung cancer in NSW. Reassuringly, these results suggest that prioritising urgent health services, such as cancer care and implementing protective mitigation measures were effective in avoiding the predicted adverse outcomes of healthcare service disruption.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
    Thronicke, A.
    Matthes, B. S.
    Grah, C.
    Grabowski, P.
    Schad, F.
    ANNALS OF ONCOLOGY, 2023, 34
  • [32] Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer
    Van Haren, Robert M.
    Delman, Aaron M.
    Turner, Kevin M.
    Waits, Brandy
    Hemingway, Mona
    Shah, Shimul A.
    Starnes, Sandra L.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 232 (04) : 600 - 605
  • [33] Impact of COVID-19 on an Australian intensive care unit: lessons learned from South Australia
    Nadkarni, Aniket
    Alderson, Steven
    Collett, Luke
    Maiden, Matthew
    Reddi, Benjamin
    Sundararajan, Krishnaswamy
    INTERNAL MEDICINE JOURNAL, 2020, 50 (09) : 1146 - +
  • [34] Real-world evidence of safety and influence for lung cancer surgery under COVID-19 pandemic in Japan
    Kato, Taketo
    Katsuya, Ryotaro
    Okado, Shoji
    Sato, Keiyu
    Noritake, Osamu
    Nakanishi, Keita
    Noguchi, Misa
    Kadomatsu, Yuka
    Ueno, Harushi
    Ozeki, Naoki
    Nakamura, Shota
    Fukumoto, Koichi
    Chen-Yoshikawa, Toyofumi Fengshi
    JOURNAL OF THORACIC DISEASE, 2023, 15 (02) : 542 - +
  • [35] Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study
    Pintos-Rodriguez, Samuel
    Visos-Varela, Irene
    Rodriguez-Fernandez, Almudena
    Zapata-Cachafeiro, Maruxa
    Pineiro-Lamas, Maria
    Herdeiro, Maria Teresa
    Garcia-Alvarez, Rosa Maria
    Figueiras, Adolfo
    Salgado-Barreira, Angel
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2024, 27 (04):
  • [36] Sex differences in comorbidities and COVID-19 mortality-Report from the real-world data
    Yoshida, Yilin
    Wang, Jia
    Zu, Yuanhao
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [37] Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study
    Ramirez-Cervantes, Karen Lizzette
    Campillo-Morales, Salvador
    Garcia-Poza, Patricia
    Quintana-Diaz, Manuel
    Huerta-Alvarez, Consuelo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (08)
  • [38] COVID-19 in Adults with Sickle Cell Disease: Data from Cerner Real-World Database
    Guarino, Stephanie H.
    Gbadebo, Bayo
    Caplan, Richard
    Ndura, Kevin
    Jurkovitz, Claudine
    BLOOD, 2022, 140 : 13172 - 13173
  • [39] REAL-WORLD EFFECTIVENESS OF EARLY TREATMENTS FOR COVID-19: EVIDENCE FROM ADMINISTRATIVE CLAIMS DATA
    Bell, C.
    Lokhandwala, T.
    Gibbons, D.
    Patel, V
    Drysdale, M.
    Wang, J.
    Lloyd, E.
    VALUE IN HEALTH, 2023, 26 (06) : S24 - S24
  • [40] Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting
    Grimaldi, Lamiae
    Verdoux, Marie
    Frank-Soltysiak, Marie
    Duclos-Vallee, Jean-Charles
    Corpechot, Christophe
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 220 - 220